Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
Palmer M, Kleiner DE, Goodman Z, Brunt E, Avigan MI, Regev A, Hayashi PH, Lewis JH, Mehta R, Harrison SA, Siciliano M, McWherter CA, Vuppalanchi R, Behling C, Miller V, Chalasani N, Sanyal AJ. Palmer M, et al. Among authors: behling c. Aliment Pharmacol Ther. 2024 Jan;59(2):201-216. doi: 10.1111/apt.17762. Epub 2023 Oct 25. Aliment Pharmacol Ther. 2024. PMID: 37877759
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.
Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA; NASH Clinical Research NetworkA list of members of the Nonalcoholic Steatohepatitis Clinical Research Network can be found in the Appendix. Brunt EM, et al. Hepatology. 2009 Mar;49(3):809-20. doi: 10.1002/hep.22724. Hepatology. 2009. PMID: 19142989 Free PMC article.
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Sanyal AJ, et al. N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28. N Engl J Med. 2010. PMID: 20427778 Free PMC article. Clinical Trial.
Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
Wang A, Blackford AL, Behling C, Wilson LA, Newton KP, Xanthakos SA, Fishbein MH, Vos MB, Mouzaki M, Molleston JP, Jain AK, Hertel P, Harlow Adams K, Schwimmer JB; NASH CRN. Wang A, et al. Among authors: behling c. Hepatology. 2024 Jun 1;79(6):1381-1392. doi: 10.1097/HEP.0000000000000644. Epub 2023 Oct 23. Hepatology. 2024. PMID: 37870272
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease.
Loomba R, Clark G, Teckman J, Ajmera V, Behling C, Brantly M, Brenner D, D'Armiento J, Fried MW, Iyer JS, Mandorfer M, Rockey DC, Tincopa M, Vuppalanchi R, Younossi Z, Krag A, Turner AM, Strnad P. Loomba R, et al. Among authors: behling c. Aliment Pharmacol Ther. 2024 May;59(10):1183-1195. doi: 10.1111/apt.17967. Epub 2024 Mar 22. Aliment Pharmacol Ther. 2024. PMID: 38516814 Review.
Investigating the Relationship Between Rare Genetic Variants and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
Wattacheril J, Kleinstein SE, Shea PR, Wilson LA, Subramanian GM, Myers RP, Lefkowitch J, Behling C, Xanthakos SA, Goldstein DB; NASH Clinical Research Network. Wattacheril J, et al. Among authors: behling c. medRxiv [Preprint]. 2024 Mar 4:2024.03.02.24303632. doi: 10.1101/2024.03.02.24303632. medRxiv. 2024. PMID: 38496563 Free PMC article. Preprint.
179 results